Mutational monitoring of EGFR T790M in cfDNA for clinical outcome prediction in EGFR-mutant lung adenocarcinoma

Podobne knjige/članki

• The emergence of T790M mutation in EGFR-mutant lung adenocarcinoma patients having a history of acquired resistance to EGFR-TKI: focus on rebiopsy timing and long-term existence of T790M
  od: Tseng, Jeng-Sen, et al.
  Izdano: (2016)
• The impact of different first-line EGFR-TKIs on the clinical outcome of sequential osimertinib treatment in advanced NSCLC with secondary T790M
  od: Huang, Yen-Hsiang, et al.
  Izdano: (2021)
• Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
  od: Hsu, Kuo-Hsuan, et al.
  Izdano: (2021)
• The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
  od: Huang, Yen-Hsiang, et al.
  Izdano: (2018)
• EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma
  od: Chen, Hsuan-Yu, et al.
  Izdano: (2016)